{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T08:42:18Z","timestamp":1776415338801,"version":"3.51.2"},"reference-count":36,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.vaccine.2016.03.048","type":"journal-article","created":{"date-parts":[[2016,3,23]],"date-time":"2016-03-23T06:10:11Z","timestamp":1458713411000},"page":"2507-2512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013\u2212May 31, 2015"],"prefix":"10.1016","volume":"34","author":[{"given":"Penina","family":"Haber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro L.","family":"Moro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paige","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily Jane","family":"Woo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Jankosky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Cano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.03.048_bib0185","unstructured":"World Health Organization. Recommended composition of influenza virus vaccines for use in the 2013-14 northern hemisphere influenza season. Geneva, Switzerland: world health Organization; February 2013 http:\/\/www.who.int\/influenza\/vaccines\/virus\/recommendations\/2013_14_north\/en\/."},{"key":"10.1016\/j.vaccine.2016.03.048_bib0190","unstructured":"Fluarix\u00ae Quadrivalent package insert, 2012 http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM220624.pdfFood and Drug Administration. Vaccines and related biological products advisory committee meeting Summary minutes; November, 2013."},{"key":"10.1016\/j.vaccine.2016.03.048_bib0195","unstructured":"http:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/BloodVaccinesandOtherBiologics\/VaccinesandRelatedBiologicalProductsAdvisoryCommittee\/ucm376493.htm."},{"key":"10.1016\/j.vaccine.2016.03.048_bib0200","unstructured":"Fluzone\u00ae Quadrivalent Package inserts, Food and Drug Administration (FDA), 2013 http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM356094.pdf."},{"key":"10.1016\/j.vaccine.2016.03.048_bib0205","unstructured":"FluLaval\u00ae, Quadrivalent package insert, 2013 http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM404086.pdf013."},{"issue":"RR07","key":"10.1016\/j.vaccine.2016.03.048_bib0210","first-page":"1","article-title":"Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), United States","volume":"62","author":"Grohskopf","year":"2013","journal-title":"MMWR"},{"issue":"August (36)","key":"10.1016\/j.vaccine.2016.03.048_bib0215","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2016.03.048_bib0220","first-page":"1","article-title":"Surveillance for safety after immunization: vaccine Adverse Event Reporting System (VAERS) United States, 1991\u22122001","volume":"52","author":"Zhou","year":"2003","journal-title":"MMWR Surveill Summ"},{"key":"10.1016\/j.vaccine.2016.03.048_bib0225","unstructured":"Medical Dictionary for Regulatory Activities. http:\/\/www.meddramsso.com. Accessed February 13, 2013."},{"key":"10.1016\/j.vaccine.2016.03.048_bib0230","first-page":"52252","article-title":"21CFR Part 600.80. Postmarketing reporting of adverse experiences","volume":"62","year":"1997","journal-title":"Fed Reg"},{"issue":"2","key":"10.1016\/j.vaccine.2016.03.048_bib0235","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","article-title":"Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program United States, 1976\u22121977","volume":"110","author":"Schonberger","year":"1979","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2016.03.048_bib0240","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Guillain-Barr\u00e9 syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.03.048_bib0245","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"25","author":"Ruggeberg","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.03.048_bib0250","series-title":"Adverse effects of vaccines: evidence and causality","year":"2012"},{"key":"10.1016\/j.vaccine.2016.03.048_bib0255","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1542\/peds.112.4.815","article-title":"Risk of anaphylaxis after vaccination of children and adolescents","volume":"112","author":"Bohlke","year":"2003","journal-title":"Pediatrics"},{"issue":"11","key":"10.1016\/j.vaccine.2016.03.048_bib0260","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.vaccine.2011.12.042","article-title":"Febrile seizures after 2010\u22122011 influenza vaccine in young children. United States: a vaccine safety signal from the vaccine adverse event reporting system","volume":"30","author":"Leroy","year":"2012","journal-title":"Vaccine"},{"issue":"March (11)","key":"10.1016\/j.vaccine.2016.03.048_bib0265","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/j.vaccine.2012.01.027","article-title":"VSD Rapid Cycle Analysis Influenza Working Group Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010\u22122011","volume":"30","author":"Tse","year":"2012","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2016.03.048_bib0270","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40264-013-0051-9","article-title":"Data Mining for Prospective Early Detection of Safety Signals in the Vaccine Adverse Event Reporting System (VAERS): a Case Study of Febrile Seizures after a 2010\u22122011 Seasonal Influenza Virus Vaccine","volume":"36","author":"Martin","year":"2013","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.vaccine.2016.03.048_bib0275","article-title":"Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990\u22122009","volume":"204","author":"Moro","year":"2011","journal-title":"A J Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2016.03.048_bib0280","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"DuMouchel","year":"1999","journal-title":"Am Stat"},{"key":"10.1016\/j.vaccine.2016.03.048_bib0285","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf"},{"issue":"April (8)","key":"10.1016\/j.vaccine.2016.03.048_bib0290","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/cid\/ciu005","article-title":"Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence","volume":"58","author":"Vellozzi","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2016.03.048_bib0295","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2105\/AJPH.2013.301651","article-title":"Cumulative risk of Guillain-Barr\u00e9 syndrome among vaccinated and unvaccinated populations during the 2009 H1N1 influenza pandemic","volume":"104","author":"Vellozzi","year":"2014","journal-title":"Am J Public Health"},{"issue":"July (2)","key":"10.1016\/j.vaccine.2016.03.048_bib0300","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/cid\/cit222","article-title":"Lack of association of Guillain-Barr\u00e9 syndrome with vaccinations","volume":"57","author":"Baxter","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2016.03.048_bib0305","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barr\u00e9 syndrome: a systematic review and meta-analysis","volume":"36","author":"Sejvar","year":"2011","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.vaccine.2016.03.048_bib0310","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1016\/j.vaccine.2014.07.073","article-title":"The vaccine safety Datalink: successes and challenges Monitoring Vaccine Safety","volume":"32","author":"McNeil","year":"2014","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.vaccine.2016.03.048_bib0315","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/aje\/kwp345","article-title":"Near real-time surveillance for influenza vaccine safety: proof-of- concept in the vaccine Safety Datalink Project","volume":"171","author":"Greene","year":"2010","journal-title":"Am J Epidemiol"},{"issue":"3","key":"10.1016\/j.vaccine.2016.03.048_bib0320","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.jaci.2015.07.048","article-title":"Risk of anaphylaxis following vaccination in children and adults","volume":"137","author":"McNeil","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2016.03.048_bib0325","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.anai.2012.09.011","article-title":"Safe administration of seasonal trivalent influenza vaccine to children with severe egg allergy","volume":"109","author":"Greenhawt","year":"2012","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.vaccine.2016.03.048_bib0330","unstructured":"Duffy J. Seizures following administration of multiple vaccines: a VSDs study. Advisory Committee in Immunization Practices (ACIP, June 2014) http:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/min-archive\/min-2014-06.pdf."},{"issue":"April (15)","key":"10.1016\/j.vaccine.2016.03.048_bib0335","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1001\/jama.2010.479","article-title":"Pandemic 2009 influenza A (H1N1) virus illness among pregnant women in the United States","volume":"303","author":"Siston","year":"2010","journal-title":"JAMA"},{"issue":"August (8)","key":"10.1016\/j.vaccine.2016.03.048_bib0340","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1586\/erv.12.72","article-title":"Safety of seasonal influenza and influenza A (H1N1) 2009 monovalent vaccines in pregnancy","volume":"11","author":"Moro","year":"2012","journal-title":"Expert Rev Vaccines"},{"issue":"April (18)","key":"10.1016\/j.vaccine.2016.03.048_bib0345","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/j.vaccine.2015.02.068","article-title":"Influenza vaccination during pregnancy: a systematic review of fetal death, spontaneous abortion, and congenital malformation safety outcomes","volume":"33","author":"McMillan","year":"2015","journal-title":"Vaccine"},{"issue":"February (6)","key":"10.1016\/j.vaccine.2016.03.048_bib0350","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1303164","article-title":"Intussusception risk after rotavirus vaccination in U.S. infants","volume":"7370","author":"Yih","year":"2014","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.vaccine.2016.03.048_bib0355","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1016\/j.vaccine.2009.01.125","article-title":"Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring","volume":"26, 27","author":"Vellozzi","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.03.048_bib0360","unstructured":"Centers for disease control and prevention. Key facts about seasonal flu vaccine. http:\/\/www.cdc.gov\/flu\/protect\/keyfacts.htm."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16300317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16300317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T23:50:06Z","timestamp":1717113006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16300317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":36,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0264410X16300317"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.03.048","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013\u2212May 31, 2015","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.03.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}